Last reviewed · How we verify
NCT05326477: REBOOT
Predictors of Behavioral Obesity Treatment Outcomes
NA trial testing Behavioral weight loss treatment in Obesity in 230 participants. Currently enrolling.
30 June 2027
Quick facts
| Lead sponsor | Rush University Medical Center |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 230 |
| Start date | 26 May 2023 |
| Primary completion | 30 June 2027 |
| Estimated completion | 30 June 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Behavioral weight loss treatment
Conditions studied
- Obesity — all drugs for Obesity →
Sponsor
Rush University Medical Center
Who can join
18 and older, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Socioceconomically disadvantaged individuals typically have poor outcomes in behavioral weight loss interventions, but the reasons for this are unknown. This project will characterize the mechanisms through which adverse daily experiences and present bias -- a cognitive adaptation to harsh and unpredictable environments -- account for disparities in weight loss outcomes.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Rationale and design of the Response to Behavioral Obesity Treatment (REBOOT) study.
Crane MM, Li M, Suzuki S, Bleil ME, et al · · 2025 · PMID 41202972 · DOI 10.1016/j.cct.2025.108138
Verify or expand the search:
- PubMed search for NCT05326477
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Rush University Medical Center trials
Trials by the same sponsor.
- NCT07278076 — Clinical Decision-Making During FEES: The Impact of Residue Amount and Location · NA · not yet recruiting
- NCT07088120 — PRECISION-CPR: PRecision-Controlled Ventilation in CPR · NA · not yet recruiting
- NCT06894719 — Oral Tranexamic Acid After Total Knee Arthroplasty · Phase 4 · not yet recruiting
- NCT06229392 — A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer · Phase 1 · withdrawn
- NCT07452406 — Protocolized Weaning of High-Flow Nasal Cannula in Adult Patients · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05326477 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rush University Medical Center
- Last refreshed: 11 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05326477.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing